MEBO Research is in touch with a biotech start-up that is researching a therapy for genetic trimethyaminuria (TMAU) and 'overload' TMAU (secondary TMAU).
It is normal in the medical research sector and invention sector for companies to be very secretive about their projects (due to patent concerns etc), so very little can be said about the project at this stage. The only info that can be given is that the research is now at a stage where it needs £/$ millions, so realistically any investors would need to be very rich. As is normal with this type of arrangement, any rich investor could find our more about the project by signing a confidentiality agreement.
A press release was written by Karen of MEBO Research which can be seen on the MEBO blog. Below is an abridged version of the release :
Are there any affluent philanthropists or serious investors out there willing to back a promising therapy for Trimethylaminuria?
Wealthy individuals are sought for investment discussions with a trusted, UK-based, biotech company looking to raise capital for continued research into a very promising TMAU therapeutic. This treatment could potentially handle both primary and secondary versions of TMAU. It is also a great opportunity for investors to have a stake in a company actively looking at therapeutics for other disorders and diseases.
Confidentiality would be assured, and any interested parties would be invited to sign a confidentiality agreement before being shown data about the project.
Please e-mail MEBO ( maria.delatorre@meboresearch.org or karen.james@meboresearch.org ) who will put you into contact immediately with the relevant company.
links :
Full press release on MEBO Research website
MEBO Research blog
MEBO Research website
Get notified of new posts by email
Join the email list via the sidebar
Join the email list via the sidebar
0 comments:
Post a Comment